Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 13;42(3):1341–1352. doi: 10.3892/ijmm.2018.3728

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhuang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Fasudil treatment inhibited the proliferation of HPMECs and HPASMCs. (A) Endothelial cell number per arteriole. (B) Concentration of NO in the serum (n=9 in Sham group, n=14 in PH group, n=18 in PH+F group, and n=11 in F group). (C) Production of NO in HPMECs with different treatments. (D) Representative figures of HPMEC migration. (E) Summarized data of the HPMEC migration rate. Representative data from four independent experiments are shown. (F) Viability of HPASMCs. (G) Summarized data of the percentage of Ki67-positive HPASMCs. (H) Representative figures of the Ki67-positive cell fraction. ^*P<0.05, ^**P<0.01 and ^***P<0.001. PH, pulmonary hypertension; F, fasudil; HPMECs, human pulmonary microvascular endothelial cells; HPASMCs, human pulmonary artery smooth muscle cells.

Fasudil treatment inhibited the proliferation of HPMECs and HPASMCs. (A) Endothelial cell number per arteriole. (B) Concentration of NO in the serum (n=9 in Sham group, n=14 in PH group, n=18 in PH+F group, and n=11 in F group). (C) Production of NO in HPMECs with different treatments. (D) Representative figures of HPMEC migration. (E) Summarized data of the HPMEC migration rate. Representative data from four independent experiments are shown. (F) Viability of HPASMCs. (G) Summarized data of the percentage of Ki67-positive HPASMCs. (H) Representative figures of the Ki67-positive cell fraction. ^*P<0.05, ^**P<0.01 and ^***P<0.001. PH, pulmonary hypertension; F, fasudil; HPMECs, human pulmonary microvascular endothelial cells; HPASMCs, human pulmonary artery smooth muscle cells.